These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39168957)

  • 1. Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure.
    Cao Y; Sun Y; Miao B; Zhang X; Zhao Q; Qi L; Chen Y; Zhu L
    High Blood Press Cardiovasc Prev; 2024 Sep; 31(5):485-492. PubMed ID: 39168957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: Insights from a 6-month real-world study.
    Tian J; Dong M; Sun X; Jia X; Zhang G; Zhang Y; Lin Z; Xiao J; Zhang X; Lu H
    Int J Cardiol; 2024 Dec; 417():132524. PubMed ID: 39244100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial.
    Wang J; Shi J; Wei J; Wang J; Gao K; Li X; Chen J; Li S; Zhao H; Wang W
    Trials; 2017 Oct; 18(1):468. PubMed ID: 29017565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic inflammation and functional capacity in elderly heart failure patients.
    Radenovic S; Loncar G; Busjahn A; Apostolovic S; Zdravkovic M; Karlicic V; Veskovic J; Tahirovic E; Butler J; Düngen HD
    Clin Res Cardiol; 2018 Apr; 107(4):362-367. PubMed ID: 29396658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
    Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
    Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure.
    Liu C; Yao L; Zhang L; Lin Y
    Pak J Pharm Sci; 2021 Nov; 34(6(Special)):2473-2478. PubMed ID: 35039262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure.
    Duan HY; Liu DM; Qian P; Wang SL; Yan LJ; Wu JT; Yang HT; Fan XW; Chu YJ
    Genet Mol Res; 2015 Dec; 14(4):15739-48. PubMed ID: 26634541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
    Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
    Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
    Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS
    Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Ruehs H; Klein D; Frei M; Grevel J; Austin R; Becker C; Roessig L; Pieske B; Garmann D; Meyer M
    Clin Pharmacokinet; 2021 Nov; 60(11):1407-1421. PubMed ID: 34086190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.
    Armstrong PW; Zheng Y; Troughton RW; Lund LH; Zhang J; Lam CSP; Westerhout CM; Blaustein RO; Butler J; Hernandez AF; Roessig L; O'Connor CM; Voors AA; Ezekowitz JA;
    JACC Heart Fail; 2022 Sep; 10(9):677-688. PubMed ID: 36049817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
    Mentz RJ; Stebbins A; Butler J; Chiang CE; Ezekowitz JA; Hernandez AF; Hilkert R; Lam CSP; McDonald K; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Sweitzer NK; Voors AA; Anstrom KJ; Armstrong PW;
    JACC Heart Fail; 2024 May; 12(5):839-846. PubMed ID: 38363272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
    Nessler J; Nessler B; Golebiowska-Wiatrak R; Palka I; Gackowski A; Kitlinski M; Melander O; Fedorowski A
    Cardiol J; 2013; 20(2):144-51. PubMed ID: 23558872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure.
    Gao Y; Xing C; Hao W; Zhao H; Wang L; Luan B; Hou A
    Int Heart J; 2020 Jan; 61(1):1-6. PubMed ID: 31875616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of left ventricular systolic function and cardiac biomarkers in pediatric severe sepsis.
    Li J; Ning B; Wang Y; Li B; Qian J; Ren H; Zhang J; Hu X
    Medicine (Baltimore); 2019 Mar; 98(13):e15070. PubMed ID: 30921240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.